BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 15875086)

  • 1. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
    Rzepecki P; Zolnierek J; Sarosiek T; Langiewicz P; Szczylik C
    Neoplasma; 2005; 52(3):238-42. PubMed ID: 15875086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
    Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
    Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.
    Hentschke P; Barkholt L; Uzunel M; Mattsson J; Wersäll P; Pisa P; Martola J; Albiin N; Wernerson A; Söderberg M; Remberger M; Thörne A; Ringdén O
    Bone Marrow Transplant; 2003 Feb; 31(4):253-61. PubMed ID: 12621459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-myeloablative allogeneic stem cell transplantation for metastatic renal cell carcinoma.
    Yun T; Lee KW; Song EG; Na II; Shin HC; Yoon SS; Park SY; Kim BK; Lee JH; Choi SJ; Lee JH; Lee KH
    Clin Transplant; 2007; 21(3):337-43. PubMed ID: 17488382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
    Childs R; Chernoff A; Contentin N; Bahceci E; Schrump D; Leitman S; Read EJ; Tisdale J; Dunbar C; Linehan WM; Young NS; Barrett AJ
    N Engl J Med; 2000 Sep; 343(11):750-8. PubMed ID: 10984562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
    Shapira MY; Or R; Resnick IB; Bitan M; Ackerstein A; Samuel S; Elad S; Zilberman I; Miron S; Slavin S
    Bone Marrow Transplant; 2003 Sep; 32(6):557-61. PubMed ID: 12953126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
    Nakagawa T; Kami M; Hori A; Kim SW; Murashige N; Hamaki T; Kishi Y; Fujimoto H; Matsuoka N; Okajima E; Komiyama M; Tobisu K; Wakayama T; Uike N; Tajima K; Makimoto A; Mori S; Tanosaki R; Takaue Y; Kakizoe T
    Exp Hematol; 2004 Jul; 32(7):599-606. PubMed ID: 15246155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
    Petersen EJ; Lokhorst HL; Verdonck LF
    Ned Tijdschr Geneeskd; 2003 Nov; 147(47):2328-32. PubMed ID: 14669540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
    Rini BI; Halabi S; Barrier R; Margolin KA; Avigan D; Logan T; Stadler WM; McCarthy PL; Linker CA; Small EJ; ; ;
    Biol Blood Marrow Transplant; 2006 Jul; 12(7):778-85. PubMed ID: 16785067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.
    Massenkeil G; Roigas J; Nagy M; Wille A; Stroszczynski C; Mapara MY; Loening S; Dörken B; Arnold R
    Bone Marrow Transplant; 2004 Aug; 34(4):309-16. PubMed ID: 15220955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fludarabine, cyclophosphamide and horse antithymocyte globulin conditioning regimen for allogeneic peripheral blood stem cell transplantation performed in non-HEPA filter rooms for multiply transfused patients with severe aplastic anemia.
    Kumar R; Prem S; Mahapatra M; Seth T; Chowdhary DR; Mishra P; Pillai L; Narendra AM; Mehra NK; Saxena R; Choudhry VP
    Bone Marrow Transplant; 2006 Apr; 37(8):745-9. PubMed ID: 16518427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
    Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
    Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft.
    Donckier V; Troisi R; Toungouz M; Colle I; Van Vlierberghe H; Jacquy C; Martiat P; Stordeur P; Zhou L; Boon N; Lambermont M; Schandené L; Van Laethem JL; Noens L; Gelin M; de Hemptinne B; Goldman M
    Transpl Immunol; 2004; 13(2):139-46. PubMed ID: 15380544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
    Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic stem cell transplantation for severe acquired aplastic anaemia using a fludarabine-based preparative regimen.
    Resnick IB; Aker M; Shapira MY; Tsirigotis PD; Bitan M; Abdul-Hai A; Samuel S; Ackerstein A; Gesundheit B; Zilberman I; Miron S; Yoffe L; Lvovich A; Slavin S; Or R
    Br J Haematol; 2006 Jun; 133(6):649-54. PubMed ID: 16704442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
    Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.